Sun Pharmaceutical Industries Limited
Equibles does not estimate personal net worth.
Kirti Ganurkar has spoken on 4 earnings calls across 1 company, most recently for Sun Pharmaceutical Industries Limited on October 30, 2026. Sun Pharmaceutical Industries Limited is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
“Let me discuss various R&D initiatives and how we are doing. We continue to invest in building an R&D pipeline for both the global generics and innovative medicine businesses, consolidated investments towards R&D for Q2 27, Stands at 7,784 million or 4.8% of sales.”
“I shall first provide you an update on global innovative medicines. In Q1 FY27, our innovative medicine sales were up 12.8% to reach US$351 million. This business accounted for 21.9% of sons.”
“In Q4 FY26, our innovative medicine sales were up to 4 million. Medicine sales for the full year FY26 were 1,400. This business accounted for the performance of this business in unit continues to be driven by growth across India and other products.”
“I shall first provide you an update on Global Innovative Medicine business. In Q3 FY26, our global innovative medicine sales were up 14.3% to reach U.S. dollar 423 million.”
Sun Pharmaceutical Industries Limited
Transcript header (unverified)
Sun Pharmaceutical Industries Limited
Drug Manufacturers - Specialty & Generic · Healthcare
Earnings Call
Sun Pharmaceutical Industries Limited
Sun Pharma Q1 FY27 Earnings Call Transcript
Sun Pharmaceutical Industries Limited
Sun Pharma Q4 FY26 Earnings Call Transcript
Sun Pharmaceutical Industries Limited
Sun Pharma Q3 FY26 Earnings Call Transcript
Sun Pharmaceutical Industries Limited
